Table 2a.
High beta-agonist use without medical review
| Outcome | SMART group (N = 151) | Standard group (N = 152) | Relative risk or rate SMART vs Standard (95% CI) | P | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N (%) | Mean (SD) | Median (IQR) | Range | N (%) | Mean (SD) | Median (IQR) | Range | Risk | Rate | ||
| At least one episode of high use | 84 (56) | 68 (45) | 1·24 (0·99–1·56) | – | 0·058 | ||||||
| Number of days of high use | 5·1 (14·3) | 1 (0–3) | 0–130 | 8·9 (20·9) | 0 (0–5) | 0–149 | – | 0·58 (0·39–0·88) | 0·010 | ||
| Number of days of high use in participants with at least one high use episode | 9·1 (18·2) | 2 (1–7·5) | 1–130 | 19·9 (27·7) | 7 (2–26·5) | 1–149 | – | – | – | ||
| Number of days of high use without medical review within 48 h in participants with at least one high use episode | 8·5 (17·8) | 2 (1–6·5) | 0–130 | 18·3 (24·8) | 5 (2–26) | 1–123 | – | 0·49 (0·31–0·75) | 0·001 | ||
| Proportion of high overuse days without medical review within 48 h compared to total high overuse days in participants with at least one high use episode | 0·94 (0·20) | 1 (1–1) | 0–1 | 0·94 (0·15) | 1 (1–1) | 0·25 –1 | – | – | – | ||